Welcome to Alt-Support-Diabetes.org

Alt-Support-Diabetes.org is under new management.

The previous webmaster was discouraged by the lack of interest in the site, and the death of Usenet in general. The active members in the alt.support.diabetes newsgroup weren't even referring to it anymore.

The domain registration for Alt-Support-Diabetes.org was paid years in advance by Mack, who was a frequent poster on the alt.support.diabetes newsgroup and an Alt-Support-Diabetes.org Webmaster. So it doesn't make sense to have a "We're shutdown" message for the next several years. However, it's probable the site will disappear on 12 April 2024.

Some of the information here is very old as the original site was established in 2001 and much of it has never been updated. But it's still a valuable resource. So it's back.

If you would like to contribute content for the site, please contact the ASD Webmaster. Articles attributed to ASD Webmaster as contributor are those for which the true author cannot be determined. If you know who should be credited, please let us know.

Alt-Support-Diabetes (ASD) is an online support group of diabetics, their families and friends. We use this forum to freely share our personal experiences, knowledge, hopes, successes and frustrations concerning diabetes and it's impact on our lives. Currently we are using three major forums: the newsgroup alt.support.diabetes, our IRC chat room, and this website.

Newsgroups are one of the oldest parts of the internet called UseNet. It even pre-dates the World Wide Web. Currently there are over 70,000 individual newsgroups.

We encourage everyone to first read the Newsgroups FAQ. It explains the few do's and don'ts and some basic information about posting to a UseNet forum such as ours.

Disclaimer

The information made available through this web site is not intended to replace the services of a physician. It is provided for informational purposes only and is not a substitute for professional medical advice.

Diabetes News from MIT

14 April 2021

MIT news feed about: Diabetes

Diabetes News from ScienceDaily

13 April 2021

Learn about early diabetes symptoms, diabetic diet information, diabetes care, type 1 diabetes, insulin resistance and type 2 diabetes. Read the latest medical research on diabetes.
  • Health benefits of breastfeeding, for mother: Lactation and visceral, pericardial fat
    As demonstrated by multiple studies, women who breastfeed have a lower risk for developing cardiovascular disease and diabetes, though the mechanisms by which these risks are reduced for lactating women are still not fully understood. Scientists recently completed a study to see if the presence of excess fat, specifically visceral and pericardial fat, could help explain this finding.
  • Parkinson's, cancer, type 2 diabetes share a key element that drives disease
    Researchers have discovered a direct link between a master sensor of cell stress and a protein that protects the power stations of cells. The same pathway is also tied to type 2 diabetes and cancer, which could open a new avenue for treating all three diseases.
  • Novel biomarker for glucocorticoids could help tailor treatments
    Researchers have uncovered pathways involved in the body's response to glucocorticoid treatments and identified a novel biomarker that could be used to monitor how these drugs work in patients.
  • Researchers develop materials for oral delivery of insulin medication
    A revolutionary technology could dramatically improve the well-being of diabetic patients through a simple and straightforward way: an insulin oral delivery system that could replace traditional subcutaneous injections without the side effects caused by frequent injection.
  • Replacing what was lost: A novel cell therapy for type I diabetes mellitus
    Researchers have developed a novel device for the safe and effective transplantation of human pancreatic beta-cells in type I diabetes mellitus (T1D). By constructing a millimeter-thick graft encapsulating beta-cells and transplanting it in diabetic mice, they were able to show that the device was removable for up to 1 year and without a significant foreign body response. This study demonstrates a novel option for cell therapy for T1D.